Setting

Asia Pacific Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Country: Trend Forecast and Growth Opportunity

Published: 30 Apr 2023 | Report Code: 10248439 | Pages: 186

Asia Pacific Clinical Trials Market will grow by 8.4% annually with a total addressable market cap of $97,110.8 million over 2023-2031, driven by the increasing number of clinical trials and increase in demand for novel therapies, rising prevalence of chronic diseases such as cancer and diabetes, the outbreak of tropical and infectious diseases such as COVID-19, and the increase in government initiatives and R&D investments. Highlighted with 99 tables and 79 figures, this 186-page report “Asia Pacific Clinical Trials Market 2022-2031 by Product Category (Drugs, Devices, Procedures), Phase (I, II, III, IV), Design (Interventional, Observational, Expanded Access), Service Type (Site Identification, Lab Services, Supply & Logistic, Decentralized Services), Indication (Oncology, Infectious Diseases, Cardiology, Obesity, Diabetes, Neurology), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific Clinical Trials Market and all its sub-segments through extensively detailed classifications.

 

Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2021-2022 and provides forecast from 2023 till 2031 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

 

In-depth qualitative analyses include the identification and investigation of the following aspects:
•  Market Structure 
•  Growth Drivers 
•  Restraints and Challenges
•  Emerging Product Trends & Market Opportunities
•  Porter’s Five Forces

 

The trend and outlook of the Asia Pacific market is forecast in an optimistic, balanced, and conservative view by taking into account COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific clinical trials market in every aspect of the classification from perspectives of Product Category, Phase, Design, Service Type, Indication, End User, and Country.

 

Based on Product Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. 
•  Trials of Drugs
    o  Small Molecule Drugs
    o  Vaccines
    o  Cell & Gene Therapy
    o  Other Drugs
•  Trials of Devices
•  Trials of Procedures

 

Based on Phase, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. 
•  Phase I
•  Phase II
•  Phase III
•  Phase IV

 

By Design, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. 
•  Interventional Studies
    o  Randomized Control Trial
    o  Adaptive Clinical Trial
    o  Non-randomized Control Trial
•  Observational Studies
    o  Cohort Study
    o  Case Control Study
    o  Cross Sectional Study
    o  Ecological Study
•  Expanded Access Trials

 

By Service Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. 
•  Protocol Designing
•  Site Identification
•  Patient Recruitment
•  Laboratory Services
•  Bioanalytical Testing Services
•  Clinical Trial Data Management Services
•  Clinical Trial Supply & Logistic Services
•  Decentralized Clinical Trial Services
•  Medical Device Testing Services
•  Other Clinical Trial Services

 

By Indication, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. 
•  Oncology
•  Infectious Diseases
•  Cardiology
•  Obesity
•  Diabetes
•  Neurology
•  Immunology
•  Pain Management
•  Other Indications

 

By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2022-2031 included in each section. 
•  Pharmaceutical and Biotechnological Companies
•  Clinical Research Organizations
•  Clinical Testing Laboratories
•  Other End Users

 

Geographically, the following national/local markets are fully investigated:
•  Japan
•  China
•  South Korea
•  Australia
•  India
•  Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

 

For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2022-2031. The breakdown of each national market by Phase, Design, and Indication over the forecast years are also included. The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

 

Selected Key Players: 
Accell Clinical Research LLC
Charles River Laboratories
ClinDatrix Inc
Clinipace
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
ICON PLC
IQVIA Holdings, Inc.
Laboratory Corporation of America (Covance Inc.)
Novo Nordisk AS
PAREXEL International Corporation
Pfizer Inc.
Pharmaceutical Product Development LLC
PhlexAsia Pacific
PRA Health Sciences
Sanofi SA
SGS SA (SGS Life Sciences)
Syneos Health Inc.
Wuxi AppTec Inc.


(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table of Contents:

1 Introduction    11
1.1 Industry Definition and Research Scope    11
1.1.1 Industry Definition    11
1.1.2 Research Scope    12
1.2 Research Methodology    15
1.2.1 Overview of Market Research Methodology    15
1.2.2 Market Assumption    16
1.2.3 Secondary Data    16
1.2.4 Primary Data    16
1.2.5 Data Filtration and Model Design    17
1.2.6 Market Size/Share Estimation    18
1.2.7 Research Limitations    19
1.3 Executive Summary    20
2 Market Overview and Dynamics    23
2.1 Market Size and Forecast    23
2.1.1 Impact of COVID-19 on World Economy    25
2.1.2 Impact of COVID-19 on the Market    28
2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery    30
2.2 Major Growth Drivers    34
2.3 Market Restraints and Challenges    41
2.4 Emerging Opportunities and Market Trends    44
2.5 Porter’s Fiver Forces Analysis    48
3 Segmentation of Asia Pacific Market by Product Category    52
3.1 Market Overview by Product Category    52
3.2 Trials of Drugs    54
3.2.1 Small Molecule Drugs    55
3.2.2 Vaccines    56
3.2.3 Cell & Gene Therapy    57
3.2.4 Other Drugs    58
3.3 Trials of Devices    59
3.4 Trials of Procedures    60
4 Segmentation of Asia Pacific Market by Phase    61
4.1 Market Overview by Phase    61
4.2 Phase I    63
4.3 Phase II    64
4.4 Phase III    65
4.5 Phase IV    66
5 Segmentation of Asia Pacific Market by Design    67
5.1 Market Overview by Design    67
5.2 Interventional Studies    69
5.2.1 Randomized Control Trial    71
5.2.2 Adaptive Clinical Trial    72
5.2.3 Non-randomized Control Trial    73
5.3 Observational Studies    74
5.3.1 Cohort Study    76
5.3.2 Case Control Study    77
5.3.3 Cross Sectional Study    78
5.3.4 Ecological Study    79
5.4 Expanded Access Trials    80
6 Segmentation of Asia Pacific Market by Service Type    81
6.1 Market Overview by Service Type    81
6.2 Protocol Designing    83
6.3 Site Identification    84
6.4 Patient Recruitment    85
6.5 Laboratory Services    86
6.6 Bioanalytical Testing Services    87
6.7 Clinical Trial Data Management Services    88
6.8 Clinical Trial Supply & Logistic Services    89
6.9 Decentralized Clinical Trial Services    90
6.10 Medical Device Testing Services    91
6.11 Other Clinical Trial Services    92
7 Segmentation of Asia Pacific Market by Indication    93
7.1 Market Overview by Indication    93
7.2 Oncology    95
7.3 Infectious Diseases    96
7.4 Cardiology    97
7.5 Obesity    98
7.6 Diabetes    99
7.7 Neurology    100
7.8 Immunology    101
7.9 Pain Management    102
7.10 Other Indications    103
8 Segmentation of Asia Pacific Market by End User    104
8.1 Market Overview by End User    104
8.2 Pharmaceutical and Biotechnological Companies    106
8.3 Clinical Research Organizations    107
8.4 Clinical Testing Laboratories    108
8.5 Other End Users    109
9 Asia-Pacific Market 2021-2031 by Country    110
9.1 Overview of Asia-Pacific Market    110
9.2 Japan    113
9.3 China    116
9.4 Australia    118
9.5 India    120
9.6 South Korea    122
9.7 Rest of APAC Region    124
10 Competitive Landscape    126
10.1 Overview of Key Vendors    126
10.2 New Product Launch, Partnership, Investment, and M&A    130
10.3 Company Profiles    131
Accell Clinical Research LLC    131
Charles River Laboratories    133
ClinDatrix Inc    136
Clinipace    137
Eli Lilly and Company    139
F. Hoffmann-La Roche Ltd.    142
ICON PLC    145
IQVIA Holdings, Inc.    148
Laboratory Corporation of America (Covance Inc.)    152
Novo Nordisk AS    156
PAREXEL International Corporation    159
Pfizer Inc.    163
Pharmaceutical Product Development LLC    168
Phlexglobal    171
PRA Health Sciences    173
Sanofi SA    175
SGS SA (SGS Life Sciences)    178
Syneos Health Inc.    181
Wuxi AppTec Inc.    184
RELATED REPORTS    186

 

List of Tables:

Table 1. Snapshot of Asia Pacific Clinical Trials Market in Balanced Perspective, 2022-2031    21
Table 2. Total Number of Registered Clinical Studies Worldwide, 2010-2021    24
Table 3. World Economic Outlook, 2021-2031    26
Table 4. World Economic Outlook, 2021-2023    27
Table 5. Scenarios for Economic Impact of Ukraine Crisis    31
Table 6. World Health Spending by Region, $ bn, 2013-2020    40
Table 7. Main Product Trends and Market Opportunities in Asia Pacific Clinical Trials Market    44
Table 8. Asia Pacific Clinical Trials Market by Product Category, 2021-2031, $ mn    52
Table 9. Asia Pacific Clinical Trials Market: Trials of Drugs by Drug Type, 2021-2031, $ mn    54
Table 10. Asia Pacific Clinical Trials Market by Phase, 2021-2031, $ mn    61
Table 11. Asia Pacific Clinical Trials Market by Design, 2021-2031, $ mn    67
Table 12. Asia Pacific Clinical Trials Market: Interventional Studies by Segment, 2021-2031, $ mn    70
Table 13. Asia Pacific Clinical Trials Market: Observational Studies by Segment, 2021-2031, $ mn    75
Table 14. Asia Pacific Clinical Trials Market by Service Type, 2021-2031, $ mn    81
Table 15. Asia Pacific Clinical Trials Market by Indication, 2021-2031, $ mn    93
Table 16. Asia Pacific Clinical Trials Market by End User, 2021-2031, $ mn    104
Table 17. APAC Clinical Trials Market by Country, 2021-2031, $ mn    111
Table 18. Japan Clinical Trials Market by Phase, 2021-2031, $ mn    115
Table 19. Japan Clinical Trials Market by Design, 2021-2031, $ mn    115
Table 20. Japan Clinical Trials Market by Indication, 2021-2031, $ mn    115
Table 21. China Clinical Trials Market by Phase, 2021-2031, $ mn    117
Table 22. China Clinical Trials Market by Design, 2021-2031, $ mn    117
Table 23. China Clinical Trials Market by Indication, 2021-2031, $ mn    117
Table 24. Australia Clinical Trials Market by Phase, 2021-2031, $ mn    119
Table 25. Australia Clinical Trials Market by Design, 2021-2031, $ mn    119
Table 26. Australia Clinical Trials Market by Indication, 2021-2031, $ mn    119
Table 27. India Clinical Trials Market by Phase, 2021-2031, $ mn    121
Table 28. India Clinical Trials Market by Design, 2021-2031, $ mn    121
Table 29. India Clinical Trials Market by Indication, 2021-2031, $ mn    121
Table 30. South Korea Clinical Trials Market by Phase, 2021-2031, $ mn    123
Table 31. South Korea Clinical Trials Market by Design, 2021-2031, $ mn    123
Table 32. South Korea Clinical Trials Market by Indication, 2021-2031, $ mn    123
Table 33. Clinical Trials Market in Rest of APAC by Country/Region, 2021-2031, $ mn    125
Table 34. Percentage of Registered Studies by Location (as of February 24, 2022)    128
Table 35. Percentage of Recruiting Studies by Location (as of February 24, 2022)    128
Table 36. Accell Clinical Research LLC: Company Snapshot    131
Table 37. Accell Clinical Research LLC: Business Segmentation    132
Table 38. Accell Clinical Research LLC: Product Portfolio    132
Table 39. Charles River Laboratories: Company Snapshot    133
Table 40. Charles River Laboratories: Product Portfolio    134
Table 41. Charles River Laboratories: Breakdown of Revenue by Division    134
Table 42. Charles River Laboratories: Breakdown of Revenue by Region    135
Table 43. ClinDatrix Inc: Company Snapshot    136
Table 44. Clinipace: Company Snapshot    137
Table 45. Clinipace: Product Portfolio    138
Table 46. Eli Lilly and Company: Company Snapshot    139
Table 47. Eli Lilly and Company: Pharmaceutical Brands    140
Table 48. Eli Lilly and Company: Clinical Trial Service    140
Table 49. Eli Lilly and Company: Breakdown of Revenue by Therapeutic Area    140
Table 50. Eli Lilly and Company: Breakdown of Revenue by Region    141
Table 51. F. Hoffmann-La Roche: Company Snapshot    142
Table 52. F. Hoffmann-La Roche: Clinical Trial Service    142
Table 53. F. Hoffmann-La Roche: Business Segmentation    143
Table 54. F. Hoffmann-La Roche: Revenue by Region    143
Table 55. ICON Plc: Company Snapshot    145
Table 56. ICON Plc: Business Segmentation    145
Table 57. ICON Plc: Product Portfolio    146
Table 58. ICON Plc: Revenue by Region, 2020, 6
Table 59. IQVIA Holdings Inc.: Company Snapshot    148
Table 60. IQVIA Holdings Inc.: Business Segmentation    149
Table 61. IQVIA Holdings Inc.: Revenue by Region, 2020, 9
Table 62. IQVIA Holdings Inc.: Product Portfolio    150
Table 63. Covance Inc.: Company Snapshot    152
Table 64. Covance Inc.: Product Portfolio    153
Table 65. Covance Inc.: Revenue by Region, 2020, 4
Table 66. Novo Nordisk: Company Snapshot    156
Table 67. Novo Nordisk: Product Portfolio    157
Table 68. Novo Nordisk: Breakdown of Revenue by Business Segment    158
Table 69. Novo Nordisk: Breakdown of Revenue by Region    158
Table 70. PAREXEL International Corporation: Company Snapshot    159
Table 71. PAREXEL International Corporation: Business Segmentation    160
Table 72. PAREXEL International Corporation: Revenue by Region, 2018, 0
Table 73. PAREXEL International Corporation: Product Portfolio    161
Table 74. Pfizer Inc.: Company Snapshot    163
Table 75. Pfizer Inc.: Business Segmentation    164
Table 76. Pfizer Inc.: Breakdown of Revenue by Product Category    164
Table 77. Pfizer Inc.: Breakdown of Revenue by Region    165
Table 78. Pfizer Inc.: Product Portfolio    165
Table 79. Pfizer Inc.: Revenue, 2018-2020, $ bn    166
Table 80. Pharmaceutical Product Development LLC (PPD): Company Snapshot    168
Table 81. Pharmaceutical Product Development LLC (PPD): Breakdown of Revenue by Division    169
Table 82. Pharmaceutical Product Development LLC (PPD): Breakdown of Revenue by Region    169
Table 83. Phlexglobal: Company Snapshot    171
Table 84. PRA Health Sciences Inc.: Company Snapshot    173
Table 85. PRA Health Sciences Inc.: Business Segmentation    174
Table 86. PRA Health Sciences Inc.: Revenue by Region, 2018, 4
Table 87. Sanofi: Company Snapshot    175
Table 88. Sanofi: Business Segmentation    176
Table 89. Sanofi: Breakdown of Revenue by Region    176
Table 90. SGS SA (SGS Life Sciences): Company Snapshot    178
Table 91. SGS SA (SGS Life Sciences): Business Segmentation    179
Table 92. SGS SA (SGS Life Sciences): Revenue by Region, 2018, 9
Table 93. Syneos Health Inc.: Company Snapshot    181
Table 94. Syneos Health Inc.: Business Segmentation    182
Table 95. Syneos Health Inc.: Revenue by Region, 2020, 2
Table 96. WuXi AppTec Inc.: Company Snapshot    184

 

List of Figures:

Figure 1. Research Method Flow Chart    15
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation    18
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2031    20
Figure 4. Asia Pacific Clinical Trials Market, 2021-2031, $ mn    23
Figure 5. Impact of COVID-19 on Business    28
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Clinical Trials Market    34
Figure 7. Percentage of Trial Participants by Country, 2015-2019    37
Figure 8. Leading Causes of Death in the World, 2000 and 2019, million    38
Figure 9. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million    39
Figure 10. World Population 65 and Over, % of Total Population, 1950-2060    39
Figure 11. Primary Restraints and Impact Factors of Asia Pacific Clinical Trials Market    41
Figure 12. Investment Opportunity Analysis    45
Figure 13. Porter’s Fiver Forces Analysis of Asia Pacific Clinical Trials Market    48
Figure 14. Breakdown of Asia Pacific Clinical Trials Market by Product Category, 2021-2031, % of Revenue    53
Figure 15. Asia Pacific Addressable Market Cap in 2023-2031 by Product Category, Value ($ mn) and Share (%)    53
Figure 16. Asia Pacific Clinical Trials Market by Product Category: Trials of Drugs, 2021-2031, $ mn    54
Figure 17. Asia Pacific Clinical Trials Market by Trials of Drugs: Small Molecule Drugs, 2021-2031, $ mn    55
Figure 18. Asia Pacific Clinical Trials Market by Trials of Drugs: Vaccines, 2021-2031, $ mn    56
Figure 19. Asia Pacific Clinical Trials Market by Trials of Drugs: Cell & Gene Therapy, 2021-2031, $ mn    57
Figure 20. Asia Pacific Clinical Trials Market by Trials of Drugs: Other Drugs, 2021-2031, $ mn    58
Figure 21. Asia Pacific Clinical Trials Market by Product Category: Trials of Devices, 2021-2031, $ mn    59
Figure 22. Asia Pacific Clinical Trials Market by Product Category: Trials of Procedures, 2021-2031, $ mn    60
Figure 23. Breakdown of Asia Pacific Clinical Trials Market by Phase, 2021-2031, % of Sales Revenue    62
Figure 24. Asia Pacific Addressable Market Cap in 2023-2031 by Phase, Value ($ mn) and Share (%)    62
Figure 25. Asia Pacific Clinical Trials Market by Phase: Phase I, 2021-2031, $ mn    63
Figure 26. Asia Pacific Clinical Trials Market by Phase: Phase II, 2021-2031, $ mn    64
Figure 27. Asia Pacific Clinical Trials Market by Phase: Phase III, 2021-2031, $ mn    65
Figure 28. Asia Pacific Clinical Trials Market by Phase: Phase IV, 2021-2031, $ mn    66
Figure 29. Breakdown of Asia Pacific Clinical Trials Market by Design, 2021-2031, % of Sales Revenue    68
Figure 30. Asia Pacific Addressable Market Cap in 2023-2031 by Design, Value ($ mn) and Share (%)    68
Figure 31. Asia Pacific Clinical Trials Market by Design: Interventional Studies, 2021-2031, $ mn    69
Figure 32. Asia Pacific Clinical Trials Market by Interventional Studies: Randomized Control Trial, 2021-2031, $ mn    71
Figure 33. Asia Pacific Clinical Trials Market by Interventional Studies: Adaptive Clinical Trial, 2021-2031, $ mn    72
Figure 34. Asia Pacific Clinical Trials Market by Interventional Studies: Non-randomized Control Trial, 2021-2031, $ mn    73
Figure 35. Asia Pacific Clinical Trials Market by Design: Observational Studies, 2021-2031, $ mn    74
Figure 36. Asia Pacific Clinical Trials Market by Observational Studies: Cohort Study, 2021-2031, $ mn    76
Figure 37. Asia Pacific Clinical Trials Market by Observational Studies: Case Control Study, 2021-2031, $ mn    77
Figure 38. Asia Pacific Clinical Trials Market by Observational Studies: Cross Sectional Study, 2021-2031, $ mn    78
Figure 39. Asia Pacific Clinical Trials Market by Observational Studies: Ecological Study, 2021-2031, $ mn    79
Figure 40. Asia Pacific Clinical Trials Market by Design: Expanded Access Trials, 2021-2031, $ mn    80
Figure 41. Breakdown of Asia Pacific Clinical Trials Market by Service Type, 2021-2031, % of Revenue    82
Figure 42. Asia Pacific Addressable Market Cap in 2023-2031 by Service Type, Value ($ mn) and Share (%)    82
Figure 43. Asia Pacific Clinical Trials Market by Service Type: Protocol Designing, 2021-2031, $ mn    83
Figure 44. Asia Pacific Clinical Trials Market by Service Type: Site Identification, 2021-2031, $ mn    84
Figure 45. Asia Pacific Clinical Trials Market by Service Type: Patient Recruitment, 2021-2031, $ mn    85
Figure 46. Asia Pacific Clinical Trials Market by Service Type: Laboratory Services, 2021-2031, $ mn    86
Figure 47. Asia Pacific Clinical Trials Market by Service Type: Bioanalytical Testing Services, 2021-2031, $ mn    87
Figure 48. Asia Pacific Clinical Trials Market by Service Type: Clinical Trial Data Management Services, 2021-2031, $ mn    88
Figure 49. Asia Pacific Clinical Trials Market by Service Type: Clinical Trial Supply & Logistic Services, 2021-2031, $ mn    89
Figure 50. Asia Pacific Clinical Trials Market by Service Type: Decentralized Clinical Trial Services, 2021-2031, $ mn    90
Figure 51. Asia Pacific Clinical Trials Market by Service Type: Medical Device Testing Services, 2021-2031, $ mn    91
Figure 52. Asia Pacific Clinical Trials Market by Service Type: Other Clinical Trial Services, 2021-2031, $ mn    92
Figure 53. Breakdown of Asia Pacific Clinical Trials Market by Indication, 2021-2031, % of Revenue    94
Figure 54. Asia Pacific Addressable Market Cap in 2023-2031 by Indication, Value ($ mn) and Share (%)    94
Figure 55. Asia Pacific Clinical Trials Market by Indication: Oncology, 2021-2031, $ mn    95
Figure 56. Asia Pacific Clinical Trials Market by Indication: Infectious Diseases, 2021-2031, $ mn    96
Figure 57. Asia Pacific Clinical Trials Market by Indication: Cardiology, 2021-2031, $ mn    97
Figure 58. Asia Pacific Clinical Trials Market by Indication: Obesity, 2021-2031, $ mn    98
Figure 59. Asia Pacific Clinical Trials Market by Indication: Diabetes, 2021-2031, $ mn    99
Figure 60. Asia Pacific Clinical Trials Market by Indication: Neurology, 2021-2031, $ mn    100
Figure 61. Asia Pacific Clinical Trials Market by Indication: Immunology, 2021-2031, $ mn    101
Figure 62. Asia Pacific Clinical Trials Market by Indication: Pain Management, 2021-2031, $ mn    102
Figure 63. Asia Pacific Clinical Trials Market by Indication: Other Indications, 2021-2031, $ mn    103
Figure 64. Breakdown of Asia Pacific Clinical Trials Market by End User, 2021-2031, % of Revenue    104
Figure 65. Asia Pacific Addressable Market Cap in 2023-2031 by End User, Value ($ mn) and Share (%)    105
Figure 66. Asia Pacific Clinical Trials Market by End User: Pharmaceutical and Biotechnological Companies, 2021-2031, $ mn    106
Figure 67. Asia Pacific Clinical Trials Market by End User: Clinical Research Organizations, 2021-2031, $ mn    107
Figure 68. Asia Pacific Clinical Trials Market by End User: Clinical Testing Laboratories, 2021-2031, $ mn    108
Figure 69. Asia Pacific Clinical Trials Market by End User: Other End Users, 2021-2031, $ mn    109
Figure 70. Breakdown of APAC Clinical Trials Market by Country, 2022 and 2031, % of Revenue    111
Figure 71. Contribution to APAC 2023-2031 Cumulative Market by Country, Value ($ mn) and Share (%)    112
Figure 72. Clinical Trials Market in Japan, 2021-2031, $ mn    114
Figure 73. Clinical Trials Market in China, 2021-2031, $ mn    116
Figure 74. Clinical Trials Market in Australia, 2021-2031, $ mn    118
Figure 75. Clinical Trials Market in India, 2021-2031, $ mn    120
Figure 76. Clinical Trials Market in South Korea, 2021-2031, $ mn    122
Figure 77. Clinical Trials Market in Rest of APAC, 2021-2031, $ mn    124
Figure 78. Growth Stage of Asia Pacific Clinical Trials Industry over the Forecast Period    126
Selected Key Players:

Accell Clinical Research LLC
Charles River Laboratory
ClinDatrix Inc
Clinipace
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
ICON PLC
IQVIA Holdings, Inc.
Laboratory Corporation of America
Novo Nordisk AS
PAREXEL International Corporation
Pfizer Inc.
Pharmaceutical Product Development LLC
PRA Health Sciences
Sanofi SA
SGS SA
Syneos Health Inc.
Wuxi AppTec Inc. 

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)